“The global needle-free injector market is projected to reach $27.65 billion by 2028″

In an exclusive interview, Sarvesh Mutha, Managing Director, IntegriMedical shares his insights on the company’s major achievements, latest offerings and way forward.

What inspired the founding of IntegriMedical, and the key milestones achieved so far?

IntegriMedical was founded in 2020 by Sarvesh Mutha, Ankur Naik, Scott McFarland, and Mark Timm with a clear vision: to transform the way medications are delivered, particularly for individuals with needle phobia. With extensive experience in the healthcare and medical device sectors, the founding team recognized a critical yet often overlooked challenge: needle fear. This affects 20–50% of children and nearly 30% of adults, leading to missed vaccinations and delayed treatments. Additionally, healthcare professionals face constant risks of needle-stick injuries and cross-contamination. To address these concerns, IntegriMedical developed the Needle-Free Injection System (N-FIS), a non-invasive, needle-free alternative to traditional syringes, designed to enhance safety, comfort, and compliance.

Since its inception, the company has reached several key milestones. In terms of regulatory approvals, N-FIS has successfully undergone clinical validation for safety, efficacy, and ease of use. It has received approvals from the Central Drugs Standard Control Organisation  (CDSCO ) in India and the CE mark (Europe).

The company has also moved into clinical expansion. It has initially piloted in pediatric care, N-FIS is now being used in gynaecology, with growing interest across other therapeutic areas. The device is currently used by over 1,000 doctors across 30+ Indian cities and has been administered to more than 50,000 patients. International adoption includes institutions like the Heim Pál National Pediatric Institute in Hungary.

IntegriMedical has built strong collaborations with leading hospitals across India and has entered a strategic partnership with the Serum Institute of India to accelerate scale and integration.

The innovation behind N-FIS has earned multiple accolades within the MedTech and healthcare communities, further validating its potential to redefine drug delivery. The innovation behind N-FIS has earned multiple accolades within the MedTech and healthcare communities, further validating its potential to redefine drug delivery. Notably, we were honored with the Product of the Year award at the Bio Spectrum Asia Excellence Awards 2024 and received the Best Healthcare Startup Award at the 6th Edition of the Startup Awards 2025 by Entrepreneur India.

From reimagining how injections are administered to building global alliances, IntegriMedical continues to push the boundaries of patient-centric innovation in healthcare.

Why is the company’s N-FIS (Needle-Free Injection System) being called a game-changer technology? Any examples of how it has significantly improved patient outcomes?

N-FIS is being called a game-changer because it solves a problem that’s been around forever, the fear, pain, and anxiety that come with needles. Instead of a sharp prick, it uses high-pressure jet stream technology to deliver medicine through the skin in under a tenth of a second. That means no needles, reduced pain, and a big drop in injection-related anxiety. The results speak for themselves. In clinical trials, 77% of people reported no pain at all, and there were no major side effects like swelling or redness. It’s been especially powerful for kids. In a study with children aged 12 to 14, 94% said they weren’t anxious before the shot, and almost half didn’t feel any pain. 

Beyond clinical trials, the technology has made a meaningful impact in real-world settings. At the Heim Pál National Pediatric Institute in Hungary, N-FIS has been used for over 4,000 haematology-oncology patients, drastically reducing injection-related distress. In India, leading hospitals including Cloudnine, KEM, Apollo Cradle, KIMS, and Rainbow Children’s Hospital have adopted the device, with nearly 1,000 doctors across Tier 1 and Tier 2 cities actively using it to enhance patient care and compliance.

N-FIS isn’t just replacing the needle, it’s replacing fear with confidence and comfort, especially for the people who need it most. 

“IntegriMedical is strategically positioning its N-FIS to meet the evolving needs of the healthcare industry”

What is the current size of the global and Indian injection market? How are you positioning the N-FIS in India and how has been the market response? 

The global market for needle-free injectors is projected to grow substantially, reaching an estimated value of $27.65 billion by 2028 at a compound annual growth rate of 14.16 percent. While traditional syringes continue to dominate, rising concerns around pain, safety, and environmental sustainability are driving a shift in preference. 

IntegriMedical is strategically positioning its N-FIS to meet the evolving needs of the healthcare industry. The company has adopted a focused, direct-to-doctor approach, initially targeting pediatric care. This model involves engaging healthcare professionals through workshops, hands-on demonstrations, and training sessions, ensuring they are fully equipped to integrate N-FIS into their practice with confidence and competence. The response from the Indian market has been highly encouraging. Adoption is steadily growing in both public and private healthcare facilities, and the overwhelmingly positive feedback from doctors highlights ease of use, safety, and improved patient experience. 

Any emerging trends in MedTech or healthcare are you watching closely? 

Yes, we are closely monitoring several transformative trends that are reshaping the MedTech and healthcare landscape. One of the most significant is the growing shift towards needle-free and non-invasive drug delivery methods aimed at improving patient comfort, compliance, and overall safety. This aligns strongly with our innovation through the N-FIS technology, which is already delivering impact in this space.

While traditionally associated with pediatric care, needle phobia is a widespread concern among adults as well. This presents broader opportunities for adoption across therapeutic areas. We recently completed a successful pilot in gynecology and officially launched N-FIS in this department earlier this month, demonstrating the technology’s versatility and relevance across clinical settings. 

Another key trend is the integration of digital health tools such as wearables and real-time monitoring, which are enabling more proactive and personalized care. Sustainability is also emerging as a core pillar of healthcare innovation. In this context, needle-free systems offer a meaningful advantage; they eliminate the need for sharps disposal, help reduce biomedical waste, and contribute to safer, more environmentally conscious care delivery. 

While needle anxiety is often linked to pediatric care, it’s a widespread issue among adults as well, creating a much larger opportunity across therapeutic areas. For instance, we recently piloted the use of N-FIS in gynecology and successfully launched it in the department earlier this month. This reinforces the platform’s adaptability across multiple clinical use cases.

Looking ahead, we are expanding our efforts into areas such as IVF treatments, growth hormone therapy, and pain management, where patient-centric, needle-free delivery can significantly improve both clinical outcomes and patient experience.

What growth opportunities are you most excited about over the next 3–5 years? 

Over the next three to five years, IntegriMedical is focused on scaling both its technology and geographic reach. The company is actively pursuing regulatory approvals in additional international markets, i.e, Europe, South America, the  Middle East, and Canada, to drive global adoption of the N-FIS device. Domestically, it is prioritizing deeper penetration across India, particularly in Tier-2 and Tier-3 cities, to ensure broader accessibility. 

Strategic partnerships with pharmaceutical companies are in progress to enable co-packaging of N-FIS with vaccines and other medications, making delivery more convenient and encouraging widespread clinical integration. Beyond pediatrics, we’re expanding into new therapeutic areas such as gynecology, infertility care, diabetes management, and IVF, where reducing patient discomfort can significantly improve treatment adherence and experience. With sustained investment in R&D, the company aims to enhance the device’s functionality and versatility. Collaborations with healthcare agencies, NGOs, and government programs will further help position needle-free injections as a mainstream, patient-friendly alternative, advancing public health goals at scale.

*This interview was first published in the special July-August 2025 issue of BioVoice eMagazine.